Who is sponsoring NCT00660192?

NCT00660192 is sponsored by Yale University.

What condition does NCT00660192 study?

NCT00660192 studies Refractory Migraine.

What is the status of NCT00660192?

NCT00660192 is currently COMPLETED.

Last reviewed 2016-02-15 · How we verify

Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches

NCT00660192 Phase 2/Phase 3 COMPLETED Results posted

The hypothesis of this study is that injection of botulinum toxin A into the muscles around the head (frontal, temporal, posterior neck, occipital) can reduce the intensity and frequency of migraine headaches by 50%.

Details

Lead sponsor	Yale University
Phase	Phase 2/Phase 3
Status	COMPLETED
Enrolment	25
Start date	2008-01
Completion	2015-07

Conditions

Refractory Migraine

Interventions

Botox
Placebo

Primary outcomes

Mean Number of Days of Decrease in Pain Level Using VAS — 4 weeks
Number of days of decreased pain (2 grades or more) on Visual Analog scale. VAS ranges from 0-10, with 0 being no pain, and 10 being worst pain.

Countries

United States